AzTrials
AzTrials

Infant, Premature, DiseasesROSANCT04500353

Routine Or Selective Application of a Face Mask for Preterm Infants at Birth: the ROSA Trial

A study testing Face mask application for CPAP and/or PPV delivery in people with Infant, Premature, Diseases and Continuous Positive Airway Pressure, run by University College Dublin at 1 site in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

International guidelines recommend giving positive pressure ventilation (PPV) by face mask to newborns who do not breathe or have a slow heart rate at birth. Preterm infants are at high risk of developing respiratory distress syndrome (RDS) and many are treated with continuous positive airway pressure (CPAP) in the… Read more about this study

Who is it for?
Ages 0 to 5 minutes
What is being tested?
Face mask application for CPAP and/or PPV delivery
Could I receive a placebo?
No, everyone receives an active treatment
How many people
201 participants
Where
1 siteIreland
Study dates
11 Oct 2020to 9 May 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 5 minutes
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Born before 32 weeks gestational age by best obstetric estimate

Who cannot join

  • Infants with major congenital anomalies

Trial locations and contacts

1 site in 1 country.

Ireland1 site
  • National Maternity Hospital

    Dublin, D02 YH21

Other trials in Ireland

About this study

Official title: A Randomised Trial of Routine or Selective Application of a Face Mask for Preterm Infants at Birth

International guidelines recommend giving positive pressure ventilation (PPV) by face mask to newborns who do not breathe or have a slow heart rate at birth. Preterm infants are at high risk of developing respiratory distress syndrome (RDS) and many are treated with continuous positive airway pressure (CPAP) in the neonatal intensive care unit (NICU). Though the majority of preterm infants breathe spontaneously at birth, many clinicians routinely apply a face mask to preterm infants shortly after birth in the delivery room (DR) to give them CPAP. However, applying a face mask may inhibit spontaneous breathing in newborns. In this study, premature babies will be randomly assigned to have a face mask routinely applied for CPAP shortly after birth; or to have a face mask selectively applied only for PPV if they are not breathing or have a slow heart beat in the first 5 minutes of life, or for CPAP if they have signs of respiratory distress after 5 minutes. The investigators will determine whether fewer participants who have the mask selectively applied receive PPV in the DR.

Read the detailed description

Newly born babies have fluid-filled lungs that they must quickly aerate after birth. Compared to infants born at term, preterm babies have greater difficulty in establishing and maintaining aeration of their lungs; this leaves them at increased risk of developing respiratory distress syndrome (RDS). Infants who develop RDS are treated with nasal continuous positive airway pressure (CPAP), and may progress to treatment with surfactant and mechanical ventilation, in the Neonatal Intensive Care Unit (NICU).

The Neonatal Task Force of the International Liaison Committee on Resuscitation (ILCOR) makes recommendations on the treatment of infants at birth. ILCOR recommends assessing the breathing and heart rate (HR) of all newborns, and:

  1. Giving positive pressure ventilation (PPV) to babies who have a HR < 100bpm, gasping or apnoea
  2. Considering giving CPAP to babies who have laboured breathing or persistent cyanosis

Most preterm infants breathe spontaneously at birth. Despite this, the majority of preterm infants have a facemask applied for respiratory support immediately after birth, usually before the HR has been determined. Clinicians presumably do this to give early support to infants they believe are at high risk of developing RDS in an attempt to prevent or lessen the severity of the disease.

There is little evidence that giving preterm infants prophylactic nasal CPAP may be superior to supportive care with oxygen. A study that compared nasopharyngeal CPAP to supportive care with oxygen performed before antenatal steroids were routinely given found no difference in the rate of development of RDS with the application of CPAP. Two more recent studies did not show that early application of nasal CPAP reduced the rate of intubation or treatment with surfactant. In these studies CPAP was given by nasal prongs and was started at 15 - 30 minutes of life, not immediately with a facemask. There is no evidence that facemask CPAP immediately after birth prevents or reduces the severity of RDS.

Application of a face mask has been demonstrated to inhibit spontaneous breathing in many term infants. Cold gas flow, such as that provided by a T-piece, can inhibit spontaneous breathing in term infants. Application of a face mask for breathing support appears to inhibit breathing in a greater proportion of preterm infants. Considerable force is applied to the head when face mask PPV is given to a mannequin in the supine position.

Routinely applying a face mask for respiratory support may be unnecessary in many premature babies. It may inhibit their spontaneous breathing and result in them receiving facemask PPV more frequently in the DR. It may also affect how well they breathe in the first day of life and increase the rate of treatment with nasal CPAP in the NICU.

METHODS

RANDOMISATION AND GROUP ASSIGNMENT Participants will be randomly assigned to "SELECTIVE" or "ROUTINE" groups in a 1:1 ratio. The group assignment schedule will be generated in blocks of 4 using a random number table, and will be stratified by gestational age (23 - 27, 28 - 31+6). It will be kept on a concealed from investigators and treating clinicians. Group assignment will be written on cards and placed in sequentially numbered, sealed, opaque envelopes. Infants of multiple gestations will be randomised as individuals.

The envelopes will be contained in 2 boxes for GA strata and kept in the NICU. The next envelope in the sequence will be taken from the appropriate box and brought to the DR, where it will be opened just before delivery.

MASKING It is not possible to mask caregivers to group assignment.

INTERVENTIONS

ALL INFANTS Infants in both groups will have their umbilical cord clamped at or after 1 minute of age; they will not have a mask applied for respiratory support during this time. Infants will then be transferred to resuscitaire, placed supine under radiant heat and have a hat applied. All infants will be placed in polyethylene bag. A pulse oximeter will be placed on the right wrist.

A T-piece device (Neopuff, Fisher \& Paykel Healthcare, Auckland NZ; or Dräger Resuscitaire (Drager healthcare, Lübeck, Germany) and round face mask (Fisher \& Paykel Healthcare, Auckland NZ) of appropriate size for the baby will be used to give respiratory support to infants in both groups. The T-piece will have gas flow set at 8 - 10 L/min, with settings PEEP 6cmH2O, and PIP 25cmH2O. There will be an air/oxygen blender in the circuit and the FiO2 will be initially set at 30%. The FiO2 will not be adjusted before 5 minutes of age.

SELECTIVE GROUP Infants assigned to the "SELECTIVE" group will be placed supine to breathe spontaneously. If SpO2 < 70% at 5 minutes and their respiratory effort is good, they will be given give free flow oxygen (i.e. the mask will be placed in front of, but not directly in contact with, the infant's face). The FiO2 may be increased at 1 minute intervals thereafter, aiming for SpO2 ≥ 90% at 10 minutes of life.

Infants in the "SELECTIVE" group will have mask PPV if they are apnoeic or have HR < 100bpm at any time in the DR. Clinicians may consider applying facemask to give CPAP if the infants breathing is laboured (i.e. there are signs of respiratory distress - grunting, intercostal/subcostal/sternal recessions) after 5 minutes of age.

ROUTINE GROUP Infants assigned to the "ROUTINE" group will be placed supine on the resuscitaire and have facemask CPAP applied as soon as possible after they arrive. If SpO2 < 70% at 5 minutes, the FiO2 may be increased at 1 minute intervals, aiming for SpO2 ≥ 90% at 10 minutes of life.

Infants in the "ROUTINE" group will have facemask PPV if they are apnoeic or have HR < 100bpm at any time in the DR. Mask respiratory support may be withdrawn as and when desired by clinical staff.

RESUCE TREATMENT All other treatments - i.e. endotracheal intubation for PPV, chest compressions, adrenaline, volume - w ill be given at the discretion of the treating clinicians and in accordance with ILCOR recommendations.

SAMPLE SIZE ESTIMATION To show a reduction in the proportion of babies receiving PPV with routine application from 60% to 40% with selective application with 80% power and α of 0.05, the investigators need to recruit 200 infants.

Being tested
Face mask application for CPAP and/or PPV delivery
Medical subject headings
Infant, Premature, Diseases, Respiratory Distress Syndrome, Newborn

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Face mask application for CPAP and/or PPV deliveryOther

    Face mask application for CPAP and/or PPV delivery

Study groups in NCT04500353
Study groupRoleWhat they receive
Routine face mask applicationActive comparatorRoutine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
Receives: Other: Face mask application for CPAP and/or PPV delivery
Selective face mask applicationExperimentalSelective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia [heart rate (HR) < 100 beats per minute (bpm)] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
Receives: Other: Face mask application for CPAP and/or PPV delivery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The proportion of participants who receive face mask PPV in the delivery room DR

    The proportion of participants who receive face mask positive pressure ventilation (PPV) in the delivery room (DR)

    Measured: Within 30 minutes of birth

Secondary outcomes (23)
  1. The proportion of participants who receive face mask CPAP in the first 5 minutes of life

    The proportion of participants who receive face mask (continuous positive airway pressure) CPAP in the first 5 minutes of life

    Measured: 5 minutes

  2. The proportion of participants who receive face mask PPV in the first 5 minutes of life

    The proportion of participants who receive face mask PPV in the first 5 minutes of life

    Measured: 5 minutes

  3. HR at 5 minutes of life

    Heart rate (HR) at 5 minutes of life

    Measured: 5 minutes

  4. SpO2 at 5 minutes of life

    Oxygen saturation (SpO2) at 5 minutes of life

    Measured: 5 minutes

  5. The proportion of participants who receive face mask CPAP in the DR

    The proportion of participants who receive face mask CPAP in the DR

    Measured: Within 30 minutes of birth

  6. Duration of PPV in the DR

    Duration of PPV in the DR

    Measured: Within 30 minutes of birth

  7. The proportion of participants who are intubated in the DR

    The proportion of participants who are intubated in the DR

    Measured: Within 30 minutes of birth

  8. The proportion of participants who receive chest compressions in the DR

    The proportion of participants who receive chest compressions in the DR

    Measured: Within 30 minutes of birth

  9. The proportion of participants who receive volume in the DR

    The proportion of participants who receive volume in the DR

    Measured: Within 30 minutes of birth

  10. The proportion of participants who receive adrenaline in the DR

    The proportion of participants who receive adrenaline in the DR

    Measured: Within 30 minutes of birth

  11. Maximum FiO2 in the DR

    Maximum fraction of inspired oxygen (FiO2) in the DR

    Measured: Within 20 minutes of birth

  12. Apgar score at 5 minutes

    Apgar score at 5 minutes (scale 0 -10, higher scores indicate better outcome)

    Measured: 5 minutes

  13. Apgar score at 10 minutes

    Apgar score at 10 minutes (scale 0 -10, higher scores indicate better outcome)

    Measured: 10 minutes

  14. Respiratory support in transport to NICU

    Respiratory support in transport to the neonatal intensive care unit (NICU)

    Measured: Within 45 minutes of birth

  15. The proportion of participants who receive NCPAP in NICU

    The proportion of participants who receive nasal CPAP in NICU

    Measured: Within one month

  16. The proportion of participants who receive endotracheal ventilation in NICU

    The proportion of participants who receive endotracheal ventilation in NICU

    Measured: Within one month

  17. The proportion of participants who receive surfactant treatment

    The proportion of participants who receive surfactant treatment

    Measured: Within one month

  18. The proportion of participants who have a pneumothorax drained

    The proportion of participants who have a pneumothorax drained

    Measured: Within one month

  19. The proportion of participants who survive free of BPD

    The proportion of participants who are alive and not receiving respiratory support or supplemental oxygen on day 28 of life

    Measured: Day 28 of life

  20. The proportion of participants who receive survive free of CLD

    The proportion of participants who are alive and not receiving respiratory support or supplemental oxygen at 36 weeks corrected age

    Measured: 36 weeks corrected

  21. The proportion of participants who receive postnatal steroids

    The proportion of participants who receive postnatal steroids

    Measured: Through study completion, an average of 2-3 months in survivors

  22. The proportion of participants who receive home oxygen therapy

    The proportion of participants who receive home oxygen therapy

    Measured: Through study completion, an average of 2-3 months in survivors

  23. The proportion of participants who die before hospital discharge

    The proportion of participants who die before hospital discharge

    Measured: Through study completion, an average of 2-3 months in survivors

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2020
  2. Study start11 Oct 2020
  3. Primary completion16 Feb 2023
  4. Study completion9 May 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomised parallel group study
Masking
None (open label)
Enrolment
201 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04500353
Sponsor's protocol ID
ROSA.01
Acronym
ROSA
Status last verified
Dec 2023
First submitted
24 Jul 2020
Last updated
5 Dec 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymised data will be shared for studies approved by the chief and principal investigators

Publications

  • Perlman JM, Wyllie J, Kattwinkel J, Wyckoff MH, Aziz K, Guinsburg R, Kim HS, Liley HG, Mildenhall L, Simon WM, Szyld E, Tamura M, Velaphi S; Neonatal Resuscitation Chapter Collaborators. Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S204-41. doi: 10.1161/CIR.0000000000000276. No abstract available.

    PubMed 26472855
  • O'Donnell CP, Kamlin CO, Davis PG, Morley CJ. Crying and breathing by extremely preterm infants immediately after birth. J Pediatr. 2010 May;156(5):846-7. doi: 10.1016/j.jpeds.2010.01.007. Epub 2010 Mar 16.

    PubMed 20236659
  • Murphy MC, McCarthy LK, O'Donnell CPF. Crying and breathing by new-born preterm infants after early or delayed cord clamping. Arch Dis Child Fetal Neonatal Ed. 2020 May;105(3):331-333. doi: 10.1136/archdischild-2018-316592. Epub 2019 May 13.

    PubMed 31085675
  • Katheria A, Arnell K, Brown M, Hassen K, Maldonado M, Rich W, Finer N. A pilot randomized controlled trial of EKG for neonatal resuscitation. PLoS One. 2017 Nov 3;12(11):e0187730. doi: 10.1371/journal.pone.0187730. eCollection 2017.

    PubMed 29099872
  • Kuypers KLAM, Lamberska T, Martherus T, Dekker J, Bohringer S, Hooper SB, Plavka R, Te Pas AB. The effect of a face mask for respiratory support on breathing in preterm infants at birth. Resuscitation. 2019 Nov;144:178-184. doi: 10.1016/j.resuscitation.2019.08.043. Epub 2019 Sep 12.

    PubMed 31521774
  • Murphy MC, McCarthy LK, O'Donnell CPF. Initiation of respiratory support for extremely preterm infants at birth. Arch Dis Child Fetal Neonatal Ed. 2021 Mar;106(2):208-210. doi: 10.1136/archdischild-2020-319798. Epub 2020 Aug 26.

    PubMed 32847832
  • Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016 Jun 14;(6):CD001243. doi: 10.1002/14651858.CD001243.pub3.

    PubMed 27315509
  • Sandri F, Ancora G, Lanzoni A, Tagliabue P, Colnaghi M, Ventura ML, Rinaldi M, Mondello I, Gancia P, Salvioli GP, Orzalesi M, Mosca F. Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial. Arch Dis Child Fetal Neonatal Ed. 2004 Sep;89(5):F394-8. doi: 10.1136/adc.2003.037010.

    PubMed 15321956
  • Goncalves-Ferri WA, Martinez FE, Caldas JP, Marba ST, Fekete S, Rugolo L, Tanuri C, Leone C, Sancho GA, Almeida MF, Guinsburg R. Application of continuous positive airway pressure in the delivery room: a multicenter randomized clinical trial. Braz J Med Biol Res. 2014 Feb;47(3):259-64. doi: 10.1590/1414-431X20133278. Epub 2014 Jan 29.

    PubMed 24554040
  • Chernick V, Avery ME. Response of premature infants with periodic breathing to ventilatory stimuli. J Appl Physiol. 1966 Mar;21(2):434-40. doi: 10.1152/jappl.1966.21.2.434. No abstract available.

    PubMed 5949048
  • Dolfin T, Duffty P, Wilkes D, England S, Bryan H. Effects of a face mask and pneumotachograph on breathing in sleeping infants. Am Rev Respir Dis. 1983 Dec;128(6):977-9. doi: 10.1164/arrd.1983.128.6.977.

    PubMed 6650989
  • Fleming PJ, Levine MR, Goncalves A. Changes in respiratory pattern resulting from the use of a facemask to record respiration in newborn infants. Pediatr Res. 1982 Dec;16(12):1031-4. doi: 10.1203/00006450-198212000-00013.

    PubMed 7155672
  • Ramet J, Praud JP, D'Allest AM, Dehan M, Gaultier C. Trigeminal airstream stimulation. Maturation-related cardiac and respiratory responses during REM sleep in human infants. Chest. 1990 Jul;98(1):92-6. doi: 10.1378/chest.98.1.92.

    PubMed 2361419
  • van Vonderen JJ, Kleijn TA, Schilleman K, Walther FJ, Hooper SB, te Pas AB. Compressive force applied to a manikin's head during mask ventilation. Arch Dis Child Fetal Neonatal Ed. 2012 Jul;97(4):F254-8. doi: 10.1136/archdischild-2011-300336. Epub 2011 Dec 5.

    PubMed 22147285

Questions about this trial

What is this clinical trial studying?

A study testing Face mask application for CPAP and/or PPV delivery in people with Infant, Premature, Diseases and Continuous Positive Airway Pressure, run by University College Dublin at 1 site in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The proportion of participants who receive face mask PPV in the delivery room DR (time frame: Within 30 minutes of birth). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04500353, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in